News
-
-
PRESS RELEASE
Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) and Curatis AG completed
Curatis Holding AG announces completion of business combination with Curatis AG, trading on SIX Swiss Exchange under CURN.SW. Specializes in orphan drugs with risk-balanced model -
-
PRESS RELEASE
Kinarus Therapeutics Holding AG publishes FY2023 Financial Statements and announces details on Business Combination with Curatis AG and Reverse Share Split
Kinarus Therapeutics Holding AG releases FY2023 Financial Statements & details on Business Combination with Curatis AG and Reverse Share Split. Postponement of 2023 Annual Report. Reverse Share Split to be implemented on 25 April 2024 -
-
PRESS RELEASE
Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business Combination with Curatis
Kinarus Therapeutics Holding AG shareholders approve resolutions for Business Combination with Curatis at Extraordinary General Meeting. Transaction closing expected by end of April 2024 -
-
PRESS RELEASE
Publication of unaudited financial statements of Kinarus Therapeutics Holding AG (only) for FY2023
Kinarus Therapeutics Holding AG releases unaudited financial statements for FY2023 in advance of extraordinary general meeting regarding Business Combination with Curatis AG. Implementation ongoing with expected closing in April 2024 -
PRESS RELEASE
Courts of Basel-Stadt have revoked bankruptcy of Kinarus Therapeutics Holding AG
Courts of Basel-Stadt have revoked the bankruptcy of Kinarus Therapeutics Holding AG, a SIX Swiss Exchange listed therapeutic drug development company. The revocation is a condition for the business combination with Curatis AG -
PRESS RELEASE
Kinarus Therapeutics Holding AG in Liquidation and Curatis AG propose to combine companies and reverse bankruptcy procedures of Kinarus Therapeutics Holding AG in Liquidation
Kinarus Therapeutics Holding AG in Liquidation and Curatis AG propose a Combination Transaction to reverse bankruptcy procedures, with conditions and a financing transaction. The combined entity will focus on drug development for speciality medicines. The planned transaction is subject to various approvals and closing conditions
